The Medical College Of Wisconsin, Inc.

The Medical College of Wisconsin, Inc., a private non-profit medical school and research institution headquartered in Wauwatosa, Wisconsin, operates as a prime recipient and contractor across federal grant and contract programs, delivering specialized clinical services, medical research, and educational training to the Department of Veterans Affairs, the National Institutes of Health, the Department of Transportation, and defense agencies. MCW competes predominately in full-and-open (non-set-aside) federal markets and does not carry SBA designations.

MCW's federal footprint splits roughly 82% prime (1,756 awards) and 18% sub (385 awards) across 2,141 total awards spanning federal contracts, indefinite delivery vehicles, and research grants. The vendor's combined potential value across all awards stands at $564.1 million, though obligated dollars ($2.99 billion across historical performance) substantially exceed potential-value ceilings, reflecting MCW's role as a large, mature federal research and clinical services provider. Recent activity shows 72 awards in 2026 (partial year), 174 in 2025, and 206 in 2024—a rising trajectory through mid-2024 that has moderated in 2026 as older awards complete.

MCW's customer concentration is heavily weighted toward health and research agencies. The top five funding agencies by award count (National Institutes of Health across multiple institutes, Veterans Integrated Service Network 12, and the National Cancer Institute) account for roughly 50% of awards. By potential value, the distribution shifts: the National Highway Traffic Safety Administration (39 awards, $232.4 million potential value) dominates, anchored by the Crash Injury Research and Engineering Network (CIREN) indefinite delivery contract ($1.5 million ceiling through August 2027); Veterans Integrated Service Network 12 (214 awards, $107.9 million) delivers perfusion services, radiology, dermatopathology, and cardiothoracic physician assistant support at the Milwaukee VA Medical Center; and the National Cancer Institute ($33.9 million across 142 awards) funds cancer research and workforce development.

MCW holds two active indefinite delivery contracts with the VA: a single-award research and academic affiliate core contract (ceiling $355,000 through January 2027) under which MCW has received multiple delivery orders for clinical support services at VA facilities in Milwaukee and surrounding regions, and a definitive contract for perfusion services at the Milwaukee VAMC (ceiling $1.78 million, completion March 2031). The NHTSA CIREN IDC is the highest-value vehicle in the top-parent-vehicles list. MCW does not hold seats on large government-wide acquisition contracts (GWACs) or other multi-award indefinite delivery vehicles visible in the source data; its contracting posture is built on agency-specific single-award IDCs and direct contract awards.

MCW's capability portfolio centers on clinical medical services (perfusion, radiology, dermatopathology, cardiothoracic support), medical research across cardiovascular disease, cancer, infectious disease, neuroscience, and immunology, vehicle safety and crash injury research, and medical education and workforce training. Representative prime work includes a $1.78 million perfusion services contract with the VA (April 2026, completion March 2031), a $4.6 million abdominal, body, and interventional radiology services contract (May 2025, completion April 2030), and a $137,106 electroencephalography and diffusion MRI data collection and analysis order from the Navy's Bureau of Medicine and Surgery (September 2024, completion March 2027). MCW's research grant footprint spans the National Institutes of Health (project grants in diabetes, heart/lung/blood disease, cancer, neurology, aging, and infectious disease), the Defense Health Agency (biomarker development for subconcussive blast exposure, $1.99 million, 2025–2029), and cooperative agreements from the NIH Office of the Director (radiation countermeasures research). MCW is a prime recipient for R01 and R21 grants, training grants (T32, R25), and K-series career-development awards; it also participates as a sub-recipient in multi-institution consortium studies led by universities and medical centers nationwide.

SCI-reported federal service contract invoicing totaled $24 million across FY2022–FY2024 ($6.9M in FY2022, $8.9M in FY2023, $8.2M in FY2024), with FTE delivery scaling from 25.2 FTEs in FY2022 to 29.3 FTEs in FY2024 across 40 prime contracts. Government-paid hourly rates on SCI-reportable contracts ranged from a 10th percentile of $37.79/hr to a median of $92.36/hr and a 90th percentile of $281.46/hr, reflecting a mix of clinical support staff, research coordinators, and highly specialized medical personnel. Across prime contracts, subs accounted for roughly 4% of total contractor hours, with three named subcontractors reported; MCW builds most of its service-contract delivery with its own staff rather than through subcontracting, indicating a vertically integrated operational model for federal clinical and research work.

MCW subcontracts to other prime institutions in limited capacity. Recent sub-award roles include participation in a University of Pittsburgh-led clinical trial on low-titer group O whole blood and tranexamic acid for traumatic injury (two sub-awards, May 2024), clinical site work under a Duke University principal investigator studying CAR-T cell reprogramming for breast cancer (May 2026 sub-award), and multi-site consortium roles in neurological, surgical, and cancer research networks led by Columbia University, Stanford, University of Chicago (SIREN emergency care clinical trials), and Children's Hospital of Philadelphia.

Eleven awards totaling $41.3 million in combined potential value are scheduled for completion within the next twenty-four months, representing recompete risk and pipeline opportunity for competitors and the vendor itself. Recent activity (December 2025–July 2026) shows sustained federal engagement across NIH institutes (neuroscience, aging, diabetes, cancer, immunology), defense agencies (biomarker development, radiation effects mitigation), and Veterans Affairs (clinical services), with award sizes typically ranging from $150,000 to $1 million for contracts and $150,000 to $750,000 for individual research project grants.